Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab
- 29 June 2007
- journal article
- case report
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 245 (11) , 1723-1725
Abstract
To describe the effect of intravitreal bevacizumab for the treatment of choroidal neovascularisation secondary to vitelliform dystrophy of the macula (Best’s disease). A 13-year-old boy with confirmed Best’s disease presented with visual acuity (VA) loss due to secondary choroidal neovascularisation (CNV). He was treated with a single injection of 1-mg bevacizumab. Best corrected VA (Snellen) fully recovered from 20/40 preoperatively to 20/20 over a period of 6 months. Optical coherence tomography (OCT) and angiography demonstrated regression of the CNV and resolution of the macular edema. A single intravitreal injection of bevacizumab may be effective to induce morphologic and functional improvement in a juvenile suffering from CNV secondary to Best’s disease.Keywords
This publication has 4 references indexed in Scilit:
- Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular DiseasesAmerican Journal of Ophthalmology, 2006
- TREATMENT OF CYSTOID MACULAR EDEMA WITH ORAL ACETAZOLAMIDE IN A PATIENT WITH BEST VITELLIFORM MACULAR DYSTROPHYRetina, 2004
- Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best diseaseAmerican Journal of Ophthalmology, 2003
- Optical coherence tomography in choroidal neovascular membrane associated with Best's vitelliform dystrophyActa Ophthalmologica Scandinavica, 2002